January 2018 in “Surgical and Cosmetic Dermatology” This review provides an up-to-date analysis of the efficacy and safety of five-alpha reductase inhibitors, specifically finasteride and dutasteride, for treating benign prostatic hyperplasia and male androgenetic alopecia, highlighting their FDA approval history and current use.
August 2016 in “Journal of Investigative Dermatology” This study found that among men unresponsive to finasteride for androgenic alopecia, 56.25% showed significant hair improvement after six months of dutasteride treatment with reasonable adverse effects.
April 2013 in “The FASEB Journal” In this study, dutasteride, but not finasteride, reduced high-grade PIN lesions more effectively in C57xFVB TRAMP mice, although both drugs increased the incidence of poorly differentiated prostate cancer.
1 citations
,
November 2010 in “Anticancer Research” This study concluded that both finasteride and dutasteride therapies significantly increased chromogranin A serum levels in men with benign prostatic hyperplasia, suggesting an activation of neuroendocrine differentiation.
20 citations
,
January 2004 in “PubMed” This review discusses the pharmacologic effects, safety, and efficacy of dutasteride and finasteride for BPH, finding similar clinical benefits but greater DHT reduction with dutasteride and reports no new trial results.
